History

NANOLEK began 2020 by receiving a prestigious award: the company took the first place in the Large Fast-growing Companies category in the TechUspekh-2019 rating.

At the end of March, NANOLEK and Efferon announced the beginning of a strategic partnership to actively market a unique medical product, in particular, two types of Efferon sorption columns.

The device is used for extracorporeal blood purification. It can also be used in the treatment of acute respiratory infections caused by SARS-CoV-2 (COVID-19).

In mid-April, the company summed up the results for 2019: the revenue amounted to 7.5 billion rubles, which is 60% higher than in 2018 (4.7 billion). The volume of investments amounted to more than 500 million rubles.

In 2019, tax payments to the budget of the Kirov Region (where the NANOLEK Biopharmaceutical Plant is located) amounted to about 100 million rubles, which is 2.5 times higher than in 2018 (40 million).

An Auditor’s Report was made by the Independent Auditor of Crow Rusaudit LLC on the annual accounting (financial) statements of Nanolek LLC for 2019, dated 10 April 2020. The Auditor made the opinion that the Accounting (financial) statements of Nanolek LLC are reliable and sufficiently reflect the financial results of operations and cash flows of Nanolek LLC.

At the end of April, the small investment company Invak, a joint venture of Nanolek LLC and the Federal State Budgetary Institution for Science and Technology of the RAS named after M. P. Chumakov, applied for registration the first domestic inactivated polio vaccine (IPV).

Nanolek LLC entered the list of systemically important organizations of the Russian economy.

The decision to include the organization in the list was taken by the government commission to increase the sustainability of the development of the Russian economy.

The industry list was posted on the website of the Ministry of Industry and Trade of Russia on 25 April 2020.

NANOLEK joined the American Chamber of Commerce (AmCham Russia).

President of NANOLEK Vladimir Khristenko: «For NANOLEK, membership in AmCham Russia is an important step in the realities we see today. The world is changing, and we all must support each other, exchanging experience and ideas, and be at the forefront of the international scientific and business plan.»

NANOLEK and COMBIOTECH announce a long-term strategic partnership to produce an entirely domestic 4-valent vaccine against human papillomavirus (HPV) Type 4 (6, 11, 16, 18), which causes cervical cancer.

According to the World Health Organization, cervical cancer (CC) is only cancer that can be prevented by primary prevention — vaccination against HPV.

The full-cycle production of the medicine will begin at the production facilities of NANOLEK in the Kirov Region; investments in the project will amount to about 1.8 billion rubles. The planned time limit for completing preclinical trials is mid-2020, clinical trials will continue until the end of 2022. At the end of 2023, it is scheduled to register and start the production of the medicine.

In May, NANOLEK and Sanofi announced a new stage in the development of a long-term partnership to localize in Russia the full-cycle production of a five-component combined pediatric vaccine developed by the company Sanofi, in particular, successful bottling of validation series.

At the biomedical production complex of NANOLEK in Kirov, the stability of three validation series of a five-component combined pediatric vaccine (Pentaxim®) is being studied with the participation of representatives of Sanofi. In accordance with the Technology Transfer Agreement, quality control will be carried out during the established period.

In the middle of June, NANOLEK was given a market authorization by the Ministry of Health of the Republic of Belarus for the socially significant drug «Hunterase» used in the treatment of the rare orphan disease Mucopolysaccharidosis type II.

The market authorization is issued for a period of 5 years.

Market authorizations for this drug were earlier issued in Russia and Kazakhstan as well.

In the middle of August, Immolab, a subsidiary of Nanolek LLC, obtained the status of the Skolkovo project participant. The company is going to develop a vaccine against COVID-19 by receiving support from the Innovation center. The relevant entry was made in the register on August 12, 2020.

In September 2020, NANOLEK was included in the first Forbes' ranking "Top Russian pharmaceutical companies". Vladimir Khristenko, President of NANOLEK, and Maxim Stetsyuk, Executive Director of the company, have been ranked among the Top Managers in Russia by the Russian Association of Managers.

Market authorizations for the drugs "Nebivolol-Nanolek" and "Ramipril" were issued by the Ministry of health of the Republic of Uzbekistan. Market authorizations shall remain valid for a period of 5 years. The Republic of Uzbekistan became the fourth export country in a row in terms of delivery of various drugs.

In November 2020, NANOLEK has won PRIORITET Awards 2020 in the nomination «Localization of production» for HUNTERASE^® — the drug used in the treatment of Hunter syndrome».

In December, NANOLEK corporate media hit the top 3 list in the «Silver Threads 2020» contest: they took the second place in the category «Best corporate account in social networks» and the third place in the nomination «Best corporate magazine».

In December 2020, the biopharmaceutical company NANOLEK and Sechenov University, one of the leading research universities in Russia, signed an agreement on strategic and technological partnership in the development of immunobiological drugs.

Intellectual and technical potential of the joint partnership will cover the entire range of activities aimed at development of immunobiological drugs, including vaccines, from the creation of a drug concept to the production of finished medicines and preclinical trials.

This cooperation is expected to become the first step on the pathway of successful partnership between fundamental science and state-of-the-art production.

NANOLEK received a registration certificate from the Ministry of Health of the Republic of Belarus for the POLIMILEX medicine — an inactivated vaccine to prevent poliomyelitis.